The path to scalable, cost-effective, and compliant AAV gene therapy is often complex, but it doesn’t have to be uncertain. 3PBIOVIAN’s AAVion® Platform offers a fully integrated solution that streamlines AAV development: from plasmid DNA manufacturing to final Drug Product. With our end-to-end capabilities, scientific support, and strategic partnerships, we help clients speed up vector manufacturing so they can focus on delivering life-changing therapies to patients, faster and with greater confidence.
AAV vector production is inherently intricate, but ensuring ensuring quality, regulatory compliance, and supply chain control adds another dimension of challenges and complexity to the vector manufacturing journey. That is why AAVion® Platform combines in-house plasmid DNA manufacturing, advanced analytical capabilities, and HEK293-based transient transfection platform, all designed for flexibility, performance, and regulatory alignment. Coupled with our optimized upstream and downstream processes and Quality by Design (QbD) principles, AAVion® Platform helps reduce variability, improves product yield and purity, and enables smooth scale-up to clinical and commercial stages.
What Makes the AAVion® Platform Different?
Our AAV Technology Manager, Artur Padzik, shared expert insights into the science and strategy behind the AAVion® Platform. Below is a condensed view on the key highlights.
- Our platform is built on robust suspension HEK293 cell-culture, optimized for AAV manufacturing. It is designed for high productivity, process consistency, and compatibility with multiple serotypes.
- AAVion® spans the full spectrum: from plasmid DNA manufacturing to AAV production, purification, analytics, and fill & finish – making it a true end-to-end and in-house manufacturing solution.
- Strong plasmids are the foundation of strong AAV. Our integrated plasmid DNA production capabilities ensure efficient timelines and smooth progress, starting from early development.
- The AAVion® Platform supports multiple serotypes and enables efficient scale-up, with consistent performance across scales, from research to GMP.
- Our AAVion® Platform was developed with regulatory expectations in mind. It comes with full GMP documentation, process data, and analytical support ready for submission at key milestones.
We believe in working alongside our clients, not just for them. The AAVion® Platform reflects this philosophy: integrated and designed to accelerate your path to the clinic.
Contact us to learn how AAVion® can support your AAV program and help you bring your therapy to patients faster.
Full articles available on Cell & Gene: